Belimumab (Benlysta) listed in ON
April 29, 2024 – Lupus Canada is pleased to share that Benlysta (indication Lupus Nephritis) is listed in Ontario effective April 17, 2024.
SUMMARY OF PRODUCT CHANGES
We are pleased to provide you with the Summary of Changes – April 2024 to Edition No. 43 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective April 30, 2024. The Edition No. 43 document will be posted on the Ministry’s website https://www.ontario.ca/document/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0 by April 30, 2024.
The Ministry has posted a new file with the listing changes for download and review (Edition No. 43, Summary of Changes – April 2024). It is accessible from the Ministry’s website: https://www.ontario.ca/document/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0.
In addition, the Formulary, Summaries of Changes and Bulletins, including a searchable electronic version of the Formulary (e-Formulary), are also accessible from the Ministry’s website: https://www.formulary.health.gov.on.ca/formulary/ – The e-Formulary will be updated on the effective date – April 30, 2024.
Exceptional Access Program (EAP) Products
Benlysta (belimumab) 120mg/5mL, 400mg/20mL Inj Sol (GSK) – Effective Date: April 17, 2024
For the treatment of patients with active lupus nephritis (LN), based on criteria.